FilingSEC EDGAR8-K
Starling Oncology Reports Q3 Revenue Growth and Positive Adjusted EBITDA
· SEC accepted
StageEarnings Release
Filing content
Starling Oncology reported Q3 2026 revenue of $169.8 million, up 24.3% year-over-year, and achieved positive Adjusted EBITDA of $3.4 million.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…